Catheter ablation of electrical storm in patients with arrhythmogenic right ventricular cardiomyopathy

Mikael Laredo, Ludivine Oliveira da Silva, Fabrice Extramiana, Nicolas Lellouche, Emilie Varlet, Denis Amet, Vincent Algalarrondo, Xavier Waintraub, Guillaume Duthoit, Nicolas Badenco, et al.

1 **Catheter Ablation of Electrical Storm in Patients with Arrhythmogenic Right**

2 **Ventricular Cardiomyopathy**

3 Mikael Laredo, MD[1]; Ludivine Oliveira Da Silva, MD[2]; Fabrice Extramiana, MD, PhD[4];

4 Nicolas Lellouche, MD, PhD[5]; Émilie Varlet, MD[|6]; Denis Amet, MD[6]; Vincent

5 Algalarrondo, MD, PhD[7]; Xavier Waintraub, MD[1]; Guillaume Duthoit, MD[1]; Nicolas

6 Badenco, MD[1]; Carole Maupain, MD[1]; Francoise Hidden-Lucet, MD[1]; Philippe Maury, MD,

7 PhD[8]; Estelle Gandjbakhch, MD, PhD[1]; GPUR Groupe Parisien Universitaire en Rythmologie

8 Investigators.

9 **Affiliations:**

10 [1]Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut de Cardiologie,

11 Paris, F-75013, France.

12 [3]University Hospital of Martinique, Martinique, France.

13 [4]AP-HP, University Hospital Bichat, Department of Cardiology, Paris, France.

14 [5]AP-HP, University Hospital Henri Mondor, Department of Cardiology, Creteil, France.

15 [6]AP-HP, Hôpital Européen Georges Pompidou, Department of Cardiology, Paris, France.

16 [7]AP-HP, Hôpital Antoine Béclère, Department of Cardiology, Clamart, France.

17 [8]Division of Cardiology, University Hospital Rangueil, Toulouse, France

18 **Brief Title:**

19 Electrical Storm Ablation in ARVC

20 **Word count:** 4973

22   None

25   **Address for correspondence:**

26   Dr. Mikael Laredo

27   Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière,

28   47-83 boulevard de l'Hôpital, 75013 Paris.

29   Email : mik.laredo@gmail.com Phone: +33 1 42 16 30 54; Fax: +33 1 42 16 30 56

30

31   **Structured Abstract**

32

33   **Background**

34   Therapeutic strategies for electrical storm (ES) in patients with arrhythmogenic right

35   ventricular cardiomyopathy (ARVC) are not well defined.

36   **Objective**

37   To report the acute and long-term results of ventricular tachycardia (VT) radiofrequency

38   catheter ablation (RFCA) as treatment for ES in patients with ARVC.

39   **Methods**

40   This multicenter study retrospectively enrolled 23 consecutive patients with ARVC (mean age

41   43.6±16.7 years; all male) who underwent 24 RFCA procedures for ES between 2003 and

42   2015.

43   **Results**

44   Thirteen (57%) patients had a previous VT RFCA;14 (61%) had right ventricular dysfunction

45   and 7 (30%) left ventricular ejection fraction ≤ 50%. The clinical VT was inducible in 19

46   (79%) procedures. Epicardial ablation was performed in 4 (17%) procedures. The median

47   number of targeted VTs was 1 [1–6]. Complete acute success (no VT inducible) was achieved

48   in 11 (46%) procedures and partial acute success (clinical VT nor inducible) in 11 (46%).

49   After a median follow-up of 3.9 years [1 month–10 years], ES recurred in 2 patients and end-

50   stage heart failure developed in 4 (17%), leading to 1 death and 3 heart transplantations. At 1-

51   year follow-up, the probability of freedom from VT recurrence was 75% and did not

52   significantly predict long-term survival. At last evaluation, 8 (35%) patients were free of non-

53   beta-blocker anti-arrhythmic drugs as compared with 1 (4%) at baseline (p = 0.02).

54   **Conclusion**

55   Catheter ablation was efficient to prevent ES recurrence in patients with ARVC. However,

56   these patients were at high risk of evolution toward ARVC-related heart failure that was not

57   associated with VT recurrence.

Introduction

Arrhythmogenic right ventricular cardiomyopathy (ARVC), a type of arrhythmogenic cardiomyopathy is a rare inherited disease associated with progressive fibrofatty myocardial remodeling affecting mostly the right ventricle (RV)[1,2]. Structural alterations associated with ARVC predispose to reentrant ventricular tachycardia (VT), and patients may experience a high burden, especially those at advanced disease stage[3]. Implantable cardioverter-defibrillators (ICDs) can efficiently prevent sudden cardiac death; however, VT events among ICD carriers with ARVC are frequent and are associated with ICD firing and increased cardiovascular morbidity[3].

Electrical storm (ES) is a life-threatening complication of structural heart diseases associated with advanced disease stage, with poor short- and long-term prognosis, that requires specific therapeutic interventions[4,5]. Patients with ARVC may experience ES, but the clinical implications and prognostic significance in this setting are less well understood.

Multiple studies have demonstrated a benefit of radiofrequency catheter ablation (RFCA) for treating ARVC-associated VT[6–8], which is therefore recommended in addition to ICD[9,2]. Several reports also suggest that RFCA is effective in reducing the ventricular arrhythmia burden in the context of ES, when evaluated in various heart diseases[4,10]. However, the benefits of RFCA as a treatment for ES in ARVC has not been specifically assessed. In this multicenter observational study, we analyzed the clinical and electrophysiological characteristics of ARVC-related ES and report the outcomes of RFCA.

Methods

Patients and definitions

Patients who underwent catheter ablation for ES from 2003 to 2015 in 7 tertiary care French centers were retrospectively included (n=23) if they 1) had a definite diagnosis of ARVC according to the 2010 revised Task Force Criteria (TFC)[11]; 2) presented ES defined by at least 3 separate sustained VT episodes or ventricular fibrillation episodes within 24 hr, documented by 12-lead electrocardiography (ECG), Holter monitoring or ICD interrogation; 3) and were referred for radiofrequency ablation as an urgent treatment for ES. Any ICD therapy (antitachycardia pacing or shock) was considered a sustained VT episode. In cases of unsuccessful antitachycardia pacing or shock, further therapies related to the same episode were not counted as an individual VT episode.

Patient screening involved reviewing all consecutive VT RFCA procedures in each center during the inclusion period, identifying those performed for ARVC-related VT (n=121 across the 7 centers), and selecting procedures that were specifically performed as urgent treatment for ES in the days or weeks after ES.

ARVC was prospectively diagnosed according to the current consensus documents and was retrospectively assessed for final diagnosis according to the 2010 revised TFC[11] at the time of data collection. The TFC criteria regarding the arrhythmia refer to an evaluation before the ES event.

Severe RV systolic dysfunction was defined by RV ejection fraction < 40% on MRI or RV angiography and/or RV fractional area change < 33% on transthoracic echocardiography in the apical 4-chamber view (major TFC). Diffuse RV involvement was arbitrarily defined by the presence of ≥ 3 akinetic or dyskinetic RV regions including RV apex, outflow tract,

105 free wall and peritricuspid region and diagnosed by echocardiography, MRI or RV

106 angiography.

107   Patients with available samples underwent mutation screening for desmosomal genes

108 *PKP2*, *DSG2*, *DSP*, *JUP* and *DSC2* by Sanger or next-generation sequencing after informed

109 written consent. All patient data were anonymized prior to data collection. No authorization

110 approval from our Institutional Committee on Human Research was required for this

111 retrospective study, in accordance with French law.

112

113 *Electrophysiological study and catheter ablation*

114 Electrophysiological studies (EPS) and catheter ablation procedures (n=24) were performed

115 under continuous invasive pressure monitoring. Programmed ventricular stimulation was

116 performed in patients in sinus rhythm at the beginning of the procedure, according to standard

117 protocols by using intravenous isoproterenol infusion if necessary. Ablation strategies

118 included VT activation mapping with characterization of the VT critical isthmus and ablation

119 targeting mid-diastolic potentials, pace-mapping based on the clinical VT 12-lead ECG

120 morphology and substrate mapping based on delineation of scar areas identified by bipolar

121 voltage mapping and maximal elimination of late potentials or Local Abnormal Ventricular

122 Activities in sinus rhythm or ventricular pacing. Ablation strategies were chosen at the

123 discretion of the electrophysiologist according to the patient's history, number of previous

124 ablation procedures, VT characteristics and clinical tolerance. For the purpose of the study,

125 ablation strategies were retrospectively classified as VT mapping (activation, entrainment and

126 pace-mapping), substrate mapping and mixed VT + substrate mapping.

127   Electro-anatomical mapping systems (CARTO, Biosense Webster Inc., Diamond Bar,

128 CA, or NavX, St. Jude Medical Inc., St. Paul, MN) were used in 19/24 procedures and a

129 multipolar electrode diagnostic catheter was used in 3/24 procedures. When indicated,

130   epicardial access was obtained by a percutaneous subxiphoid puncture. Procedures were

131   performed with 4-mm conventional or irrigated-tip radiofrequency catheters. Induced VTs

132   were considered clinical when the 12-lead ECG morphology was identical to the clinical VT

133   with the same rate ± 20 bpm. Complete acute success was defined as no sustained VT induced

134   at final EPS, partial acute success as no clinical VT induced, acute procedural failure as the

135   ability to induce a sustained clinical VT. Procedural success was considered undetermined

136   when no VT was induced at the beginning of the procedure or when no final EPS was

137   performed.

138

139   *Follow-up and endpoints*

140   Patients were followed routinely by their treating electrophysiologist or cardiologist. VT

141   recurrence was defined as the recurrence of any documented sustained VT lasting ≥ 30 sec or

142   any appropriate ICD therapy including anti-tachycardia pacing. Recurrence of ES followed

143   the same definition as for the initial presentation. Medical records and stored electrograms

144   from ICD interrogations were reviewed at each center to identify VT recurrence and assess

145   ICD therapies.

146   *Data collection*

147   Data regarding demographics, medical history, clinical evaluation, 12-lead ECG, genetic

148   analyses, echocardiography and computed tomography imaging, ICD interrogations,

149   electrophysiology studies and catheter ablation procedures were retrieved from medical

150   records at each center.

151   *Statistical analyses*

152   Continuous data are reported as mean ± SD or median [range] for normally or non-normally

153   distributed data. Categorical variables are presented as number (%). Comparative statistics

154   involved the exact Fisher test. Survival curves were created with the Kaplan-Meier method,

155 with comparisons involving the Log-Rank test. Univariate regression analyses were

156 performed with the Cox proportional-hazards model, estimating hazard ratios (HRs) and 95%

157 confidence intervals (CIs). All tests were two-sided, with $p < 0.05$ denoting statistical

158 significance. All statistical analyses involved using IBM SPSS v23 (IBM Corp., Armonk,

159 NY, USA).

160

161 **Results**

162

163 *Patient characteristics*

164 Overall, 23 consecutive patients with ARVC (mean age at diagnosis 43.6±16.7 years)

165 underwent 24 RFCA procedures for ES were retrospectively enrolled (Table 1). All patients

166 had a definite ARVC diagnosis according to the 2010 revised TFC[11]. Individual TFC criteria

167 are available in Supplementary Table 1 and ES episode descriptions are in Supplementary

168 Table 2. Patients presented ES at a mean of 7.3 ± 9.6 years after ARVC diagnosis. Three

169 (13%) patients had a history of resuscitated sudden cardiac death. Overall, 17 (74%) patients

170 had previously experienced at least one episode of sustained VT, 18 (83%) had previous ICD

171 placement, and 13 (57%) had previous VT catheter ablation (median 1, range [0–7]). Results

172 from genetic analysis were available for 15 (65%) patients; 10/15 (67%) carried an ARVC-

173 related pathogenic mutation (Table 1). Twelve (52%) patients presented incessant not-well

174 tolerated VT despite repeated intravenous amiodarone boluses, electrical cardioversion or

175 general anesthesia (Supplementary Table 2). The median number of ICD shocks related to ES

176 was 13 (range 1–30). Most patients showed typical depolarization and repolarization

177 abnormalities (Supplementary Table 1). Overall, 14 (61%) patients had severely impaired RV

178 systolic function, 8 (35%) had at least mild LV systolic function impairment with LV ejection

179 fraction (LVEF) ≤ 50%, and one had severe LV dysfunction (LVEF = 20%).

180

Procedural characteristics and acute results

In most cases, a single monomorphic VT was responsible for the ES [20 (83%) procedures],

whereas multiple sustained monomorphic VTs could be induced by ventricular programmed

stimulation in 15 (63%) procedures (Table 2 and Supplementary Table 2 for individual

electrophysiogical data). Median clinical VT rate was 171 bpm (range 130–230).

Endocardial+epicardial mapping and ablation was performed in 4 (17%) procedures. In one

patient with severely depressed LVEF, the RFCA procedure was performed under

extracorporeal membrane oxygenation support for incessant hemodynamically unstable VT.

Irrigated radiofrequency was used in 21 (88%) procedures and non-irrigated radiofrequency

in 3 (12%). Ablation strategies consisted of VT mapping [7 (29%)], substrate mapping [8

(33%)] and mixed VT and substrate mapping [9 (38%)]. The median number of targeted VT

was 1 [range 1–6] and targeted RV areas 1 [1–5]. More than one RV area was targeted in 9

(38%) patients and 10 (42%) procedures. Targeted RV areas included RV free wall [12

(50%)], RV outflow tract [7 (29%)], RV sub-tricuspid region [9 (38%)], RV septum [2 (8%)]

and left ventricle [2 (8%)] (Supplementary Table 2). Complete acute success was achieved in

11 (46%) procedures and partial acute success in 11 (46%). An undetermined result was

reported in 2 (8%) procedures. There was no acute procedural failure. Acute procedural

complications included one minor groin hematoma and one femoral arteriovenous fistulae

requiring percutaneous treatment.

Long-term outcomes

During a median follow-up of 3.9 years (range 1 month–10 years), ES recurred in 2 patients

(see Supplementary Table 3 for detailed individual outcomes). The first patient underwent

redo RFCA for ES at 2.5 years after the initial procedure but died 2.8 years later in the post-

205 operative course of heart transplantation (HT) that was performed for end-stage heart failure.

206 The other had ES recurrence 1.5 years after the initial ES; he underwent redo RFCA and

207 remained free of VA recurrence in a subsequent follow-up period of 1 year. The cumulative

208 probability of freedom from ES recurrence at 1 and 5 years after the initial ES RFCA

209 procedure was 100% and 85% (Figure 1A & Supplementary Table 4 for 95% CIs of survival

210 rates). Six patients had VT recurrence during follow-up. All VT recurrences were

211 monomorphic and triggered appropriate ICD therapies (details in Supplementary Table 3).

212 Five patients underwent redo VT ablation, including 4 who remained free of VT recurrence at

213 the end of follow-up. The cumulative probability of freedom from VT recurrence at 1 and 5

214 years after the initial ES RFCA procedure was 77% and 66% (Figure 1B). Complete acute

215 procedural success was not significantly associated with freedom from VT recurrence after

216 the initial ES ablation procedure (HR = 0.27, 95% CI [0.05–1.43], p = 0.13). Baseline LVEF

217 and presence of RV systolic dysfunction were not associated with VT recurrence. After the

218 initial ES catheter ablation procedure, 4 patients had ICD placement, so all patients had an

219 ICD during follow-up. At the end of follow-up, 8 (35%) patients were not taking non-beta-

220 blocker anti-arrhythmic agents as compared with 1 (4%) at baseline (p = 0.02).

221 　　　Three patients died during follow-up (2 immediately after HT and 1 from hemorrhagic

222 stroke while awaiting HT) and 1 patient survived HT. These 4 patients had end-stage heart

223 failure related to ARVC with severe biventricular systolic dysfunction. The cumulative

224 probability of survival without death or HT at 1 and 5 years after initial ES catheter ablation

225 was 90% and 84% (Figure 2A). Neither VT recurrence during follow-up (HR 2.32, 95% CI

226 [0.32–16.74], p = 0.40) (Figure 2B) nor complete acute procedural success (HR 0.96, 95% CI

227 [0.13–6.86], p = 0.97) was significantly associated with death or heart transplantation during

228 follow-up, Among the 4 patients who died or underwent HT, 2 did not show VA recurrence

229 after the initial RFCA. Baseline LVEF was significantly associated with risk of death or HT

230 (HR for a 1% LVEF increase: 0.90, 95% CI [0.81–60.99], p = 0.045) (Figure 2C). The

231 detailed course of adverse events during follow-up is in Supplementary Table 3.

232

233 **Discussion**

234

235 This is the first study to report outcomes after RFCA performed for ES in patients with

236 ARVC. RFCA was safe and effective to prevent ES recurrence, with no periprocedural

237 adverse outcomes and only 2 ES recurrences. In addition, 1) patients presenting ES frequently

238 had ARVC with overt RV structural alterations and a significant history of ventricular

239 arrhythmias with previous VT ablations, 2) usually one monomorphic VT was responsible for

240 the ES event, 3) complete procedural success was achieved in 11 (46%) procedures and

241 elimination of the clinical VT could be achieved in 22 (92%), 4) the 5-year estimated VT

242 recurrence rate was 34%, and 5) we found a 24% 5-year estimated rate of mortality or HT

243 after an ES event — mortality consecutive to heart failure related to ARVC structural

244 dysfunction and that was not associated with the long-term arrhythmic outcome after RFCA.

245

246 *Clinical features associated with ES in ARVC*

247 In our series of ARVC patients presenting ES and referred for RFCA, we found a high

248 prevalence of electrical and structural abnormalities as compared with large cohorts of ARVC

249 patients[12,13]. Most patients had severe RV systolic dysfunction, 35% had LV dysfunction,

250 43% showing epsilon-wave and 53% previous VT RFCA. All were male, and the mean age at

251 ES was 43.6 years, when most ARVC patients are symptomatic[14]. Overall, 66% of screened

252 individuals had a pathologic mutation in desmosomal genes, which is higher than what is

253 usually found in ARVC cohorts and associated with worse prognosis[12]. These high-risk

254 features were also more frequent than in a recent large cohort of ICD carriers[15]. However,

12

patient characteristics were overall comparable to studies enrolling ARVC patients

undergoing VT ablation[8,16], except in terms of the frequency of ECG depolarization

abnormalities and previous VT ablation, which were more frequent in our patients and

suggests that ARVC patients experiencing ES have a more extensive electrical substrate than

those with isolated VT.

The study of Carbuciccio *et al*. reported outcomes of ES ablation among 95 patients

(76% with ischemic cardiomyopathy and 13 [14%] with ARVC][10]. Mean age was higher than

in our series (64±13 years), 38% of patients had several clinical VTs and 11% required

periprocedural hemodynamical support. In our ARVC series, a single VT was responsible for

most of the ES; we did not observe any patient with repetitive polymorphic VT; and only 1

patient had > 5 inducible VTs. Hemodynamic instability was rare, which is probably related

to the conserved or mildly impaired LV function in most ARVC patients.

Procedural outcomes

We report a relatively low rate of complete acute procedural success, 46%, as compared with

the 72% in the largest series of ES ablation[10] and the 71% to 77% in a recent series of VT

ablation in ARVC[8]. The low rate may have several explanations: first, our series included rare

patients across a 12-year period that saw major progresses in RFCA techniques. Particularly,

a combined endocardial+epicardial approach, associated in several studies with improved

acute procedural success and long-term freedom from VT recurrences[7,8,17,18], was performed

in only 18% of our cases because of the inclusion period. Epicardial ablation likely would

have enhanced our acute and late success rates. Nonetheless, recent evidence has shown a

negative correlation between the extension of RV endocardial scarring and the presence of

arrhythmogenic epicardial scar because of disease progression from the epicardium to the

endocardium[19]. Considering the severity of RV involvement in our series, a first-line

280   epicardial approach would probably have been less profitable than in a regular case of VT

281   RFCA in ARVC. Also, epicardial access may be deleterious in patients with ES by

282   compromising the chance of inducing the clinical VT and by increasing the risk of

283   hemodynamic instability during VT mapping. That being said, there is sufficient evidence to

284   favor an initial endocardial+epicardial approach in stable patients presenting ES, and it should

285   be particularly considered in patients with early-stage ARVC or when evidence for extensive

286   epicardial substrate or clinical VT originating from the epicardium is known from a previous

287   VT ablation. Second, 3D electroanatomic mapping systems, which significantly improve VT

288   RFCA[7] in ARVC, were unavailable at the time of RFCA in 25% of our cases. Finally, our

289   patients had marked RV structural alterations, which are correlated with scar extension and

290   diffuse arrhythmogenic substrate[20].

291   All our patients were amenable to RFCA, including those with several previous

292   ablations and biventricular dysfunction, and no severe complications were observed,

293   including no hemodynamic deterioration. Although we obtained a relatively low rate of

294   complete acute success, clinical VT could not be induced in most patients (92%) and only 2

295   patients experienced ES recurrence after RFCA. This finding may suggest that inability to

296   induce clinical VT is a reasonable endpoint to prevent ES recurrence. Catheter ablation is a

297   Class I indication as an urgent first-line treatment for ES[21] regardless of the heart disease, and

298   should also be considered as such in ARVC.

299

300   ***Long-term survival after ES in ARVC***

301   ES is an independent predictor of death among various heart diseases[5]. However, the

302   mechanisms by which ES leads to increased mortality remain poorly understood, and its

303   clinical significance in ARVC as compared with other heart diseases is poorly established. In

304   a recent meta-analysis of 471 ES patients from 39 publications, only 22 had ARVC, which

305 precluded generalizing findings to patients with ARVC[4]. A key question is whether RFCA

306 improves long-term survival after an ES event in ARVC, or if RFCA only permits a palliative

307 benefit of alleviating the VT burden. In the study of Carbuciccio *et al*., long-term survival

308 was worse for patients for whom RFCA resulted in partial success or procedural failure, with

309 a significant occurrence of sudden cardiac death related to untractable ES recurrence[10]. In the

310 above-mentioned meta-analysis, arrhythmic sudden death accounted for 23% of long-term

311 mortality[4]. These findings suggest that VA recurrence after RFCA for ES contributes to

312 survival to some extent. In our study specifically addressing ARVC, we found no association

313 between long-term survival and procedural success or VT/VF recurrence during follow-up.

314 Fatal outcomes were all related to ARVC-related structural dysfunction, and we found no

315 temporal association between VT recurrence and mortality or HT. These results are in line

316 with a recent multicenter observational study finding no difference in survival in RFCA-

317 versus AAD-treated patients despite a significantly reduced VT burden in the former group[22].

318 Also, a prospective study including patients with ES occurring in various forms of

319 cardiomyopathies showed that patients with ES shared many similarities with those

320 presenting severe decompensated heart failure and a comparable prognosis[23]. ES clinical

321 presentation and accessibility to RFCA seems more favorable in ARVC than in the overall ES

322 landscape, but eliminating the arrhythmic substrate responsible for ES may have little impact

323 on the progressive structural deterioration. For ARVC patients with advanced disease, ES

324 might be considered an epiphenomenon of disease progression toward end-stage heart failure.

325

326 ***Limitations***

327 The main limitations of our study are its retrospective nature and the long inclusion period.

328 The low number of included patients over a 12-year inclusion period in a specialized center

329 certainly does not reflect the ES incidence in ARVC, data that would have been interesting to

330   report but given the nature of our study, cannot be provided. The patient screening

331   methodology that we used identified patients who underwent VT ablation specifically for ES

332   treatment and not those who were managed medically. A recent retrospective study of 31 ICD

333   carriers reported an annual incidence of ES of 31% [24], so the definition of ES itself

334   encompasses diverse and arrhythmia profiles that range from 3 separate episodes of well-

335   tolerated VT to the critical situation of incessant VT, which was the most frequent scenario in

336   our study. The RFCA strategies and techniques were heterogenous, considering that they

337   were performed in 7 different centers over 12 years, beginning in 2003. Much progress has

338   been made in the field of VT ablation over the last decade, including refinement of

339   electroanatomic mapping, substrate identification and epicardial ablation; therefore, our acute

340   and late results might have been improved if RFCA procedures were performed in a

341   contemporary setting. Also, we lack quantitative data regarding ICD data at baseline and

342   during follow-up, which would have been helpful to assess the reduction in VT burden

343   provided by RFCA. Finally, the small study population warrants caution in interpreting

344   descriptive and survival statistics.

345

346   **Conclusions**

347

348   Patients with ARVC experiencing ES exhibited features of structurally advanced disease and

349   frequently had a long history of ventricular arrhythmias, but ES was characterized by

350   relatively good hemodynamic tolerance and single monomorphic VT in most cases. Despite a

351   relatively low complete procedural success rate, RFCA was effective in preventing ES

352   recurrence. Long-term mortality was significant and was associated with the ARVC-related

353   structural dysfunction rather than the arrhythmic outcome. Further studies are needed to

354   define the optimal first-line strategy for ES ablation in the setting of ARVC.

355

Acknowledgments

357

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380   **References**

381   1.   Gandjbakhch E, Redheuil A, Pousset F et al.: Clinical Diagnosis, Imaging, and Genetics

382   of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Coll Cardiol

383   2018; 72:784–804.

384   2.   Towbin JA, McKenna WJ, Abrams DJ, et al.: 2019 HRS Expert Consensus Statement on

385   Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy.

386   Heart Rhythm 2019

387   3.   Schinkel AFL: Implantable Cardioverter Defibrillators in Arrhythmogenic Right

388   Ventricular Dysplasia/Cardiomyopathy: Patient Outcomes, Incidence of Appropriate and

389   Inappropriate Interventions, and Complications. Circ Arrhythm Electrophysiol 2013;

390   6:562–568.

391   4.   Nayyar S, Ganesan AN, Brooks AG, et al.: Venturing into ventricular arrhythmia storm:

392   a systematic review and meta-analysis. Eur Heart J 2013; 34:560–571.

393   5.   Guerra F, Shkoza M, Scappini L, et al. Role of electrical storm as a mortality and

394   morbidity risk factor and its clinical predictors: a meta-analysis. Europace 2014; 16:347–

395   353.

396   6.   Marchlinski FE, Zado E, Dixit S, et al.: Electroanatomic Substrate and Outcome of

397   Catheter Ablative Therapy for Ventricular Tachycardia in Setting of Right Ventricular

398   Cardiomyopathy. Circulation 2004; 110:2293–2298.

399   7.   Philips B, Madhavan S, James C, et al.: Outcomes of Catheter Ablation of Ventricular

400   Tachycardia in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circ

401   Arrhythm Electrophysiol 2012; 5:499–505.

402 8.   Santangeli P, Zado ES, Supple GE, et al.: Long-Term Outcome With Catheter Ablation

403   of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular

404   Cardiomyopathy. Circ Arrhythm Electrophysiol 2015; 8:1413–1421.

405 9.   Corrado D, Wichter T, Link MS, et al.: Treatment of arrhythmogenic right ventricular

406   cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J

407   2015; 36:3227–3237.

408 10. Carbucicchio C, Santamaria M, Trevisi N, et al.: Catheter Ablation for the Treatment of

409   Electrical Storm in Patients With Implantable Cardioverter-Defibrillators: Short- and

410   Long-Term Outcomes in a Prospective Single-Center Study. Circulation 2008; 117:462–

411   469.

412 11. Marcus FI, McKenna WJ, Sherrill D, et al.: Diagnosis of arrhythmogenic right

413   ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria.

414   Eur Heart J 2010; 31:806–814.

415 12. Groeneweg JA, Bhonsale A, James CA, et al.: Clinical Presentation, Long-Term Follow-

416   Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular

417   Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet 2015;

418   8:437–446.

419 13. Dalal D: Arrhythmogenic Right Ventricular Dysplasia: A United States Experience.

420   Circulation 2005; 112:3823–3832.

421 14. Dalal D, Jain R, Tandri H, et al.: Long-Term Efficacy of Catheter Ablation of

422   Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular

423   Dysplasia/Cardiomyopathy. J Am Coll Cardiol 2007; 50:432–440.

424   15.   Orgeron GM, James CA, Te Riele A, et al.: Implantable Cardioverter- Defibrillator

425   Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of

426   Appropriate Therapy, Outcomes, and Complications. J Am Heart Assoc 2017;

427   6:e006242.

428   16.   Souissi Z, Boulé S, Hermida J-S, et al.: Catheter ablation reduces ventricular tachycardia

429   burden in patients with arrhythmogenic right ventricular cardiomyopathy: insights from

430   a north-western French multicentre registry. EP Eur 2018; 20:362–369.

431   17.   Bai R, Di Biase L, Shivkumar K, et al.: Ablation of Ventricular Arrhythmias in

432   Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Arrhythmia-Free

433   Survival After Endo-Epicardial Substrate Based Mapping and Ablation. Circ Arrhythm

434   Electrophysiol 2011; 4:478–485.

435   18.   Philips B, te Riele ASJM, Sawant A, et al.: Outcomes and ventricular tachycardia

436   recurrence characteristics after epicardial ablation of ventricular tachycardia in

437   arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2015;

438   12:716–725.

439   19.   Berruezo A, Acosta J, Fernández-Armenta J, et al.: Safety, long-term outcomes and

440   predictors of recurrence after first-line combined endoepicardial ventricular tachycardia

441   substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate

442   distribution pattern. A prospective multicentre study. Europace 2016; :euw212.

443   20.   Kirubakaran S, Bisceglia C, Silberbauer J, et al.: Characterization of the arrhythmogenic

444   substrate in patients with arrhythmogenic right ventricular cardiomyopathy undergoing

445   ventricular tachycardia ablation. EP Eur 2017; 19:1049–1062.

446   21.   Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.: 2015 ESC Guidelines for the

447   management of patients with ventricular arrhythmias and the prevention of sudden

448   cardiac death. Eur Heart J 2015; 36:2793–2867.

449   22.   Mahida S, Venlet J, Saguner AM, et al.: Ablation compared with drug therapy for

450   recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy:

451   Results from a multicenter study. Heart Rhythm; 2018.

452   23.   Guerra F, Flori M, Bonelli P, et al.: Electrical storm and heart failure worsening in

453   implantable cardiac defibrillator patients. Europace 2015; 17:247–254.

454   24.   Yin K, Ding L, Hua W, Zhang S: Electrical Storm in ICD Recipients with

455   Arrhythmogenic Right Ventricular Cardiomyopathy: ES IN ARVC PATIENTS. Pacing

456   Clin Electrophysiol 2017; 40:683–692.

457

458

Figure title and legends

Figure 1. Long-term arrhythmic outcomes in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC) after catheter ablation for electrical storm (ES). A) Kaplan-Meier representation of cumulative probability of freedom from ES recurrence after the initial ES ablation procedure. B) Kaplan-Meier representation of cumulative probability of freedom from ventricular tachycardia (VT) recurrence after the initial ES ablation procedure.

Figure 2. Long-term survival in patients with ARVC after catheter ablation. A, B, C) Kaplan-Meier representation of cumulative probability of survival without death and heart transplantation after the initial ES ablation procedure with and without VT recurrence and LVEF > 50% and ≤ 50%. Vertical bars represent the 95% confidence interval of the estimated probability.

Table 1: Characteristics of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) undergoing catheter ablation as urgent treatment for electrical storm (ES) (n=23)

Age at procedure, years	43.6 ± 16.7
Time from diagnosis to ES, years	3.4 (-4.4–39.2)
Male sex	23 (100)
Definite ARVC diagnosis (TFC)	23 (100)
Pathogenic mutation	
PKP2	6 (26)
DSG2	1 (4)
DSP	1 (4)
PKP2 + DSP VUS	2 (9)
None	5 (12)
Unknown	8 (35)
ECG abnormalities	
Inverted T-waves beyond V2	17 (74)
Epsilon wave	10 (43)
QRS width in V1, ms	108 ± 20
Structural abnormalities	
LVEF	56 (20–70)
LVEF ≤ 50%	7 (30)
RVEF	45 (29–63)
RV systolic dysfunction*	14 (61)
Diffuse RV involvement	16 (70)
ICD before ablation	19 (83)
Previous VT ablation	12 (52)

Anti-arrhythmic drugs

    Beta-blocker alone   6 (26)

    Flecainide   10 (43)

    Amiodarone   4 (17)

    Flecainide + sotalol   1 (4)

    Sotalol   1 (4)

    None   1 (4)

ES clinical tolerance

    Syncope   12 (52)

    Hemodynamic failure   4 (17)

Data are n (%), median (range) or mean ± SD.

*: defined by RVEF < 40% with RV angiography or fractional area change < 33% with transthoracic echocardiography.

Table 2: Arrhythmia characteristics and results of electrophysiological study for each ES catheter ablation procedure (n=24)

Clinical VT	
Number of documented VTs	1 (1–2)
>1 documented VT	4 (17)
Clinical VT morphology*	
LBBB, inferior axis	12
LBBB, superior axis	10
RBBB	2
Electrophysiological study and catheter ablation	
Clinical VT cycle length	348 ± 51
>1 induced VT	15 (63)
Use of a 3D electroanatomic mapping system	18 (75)
Number of induced VTs	2 ± 1.36
Number of targeted VTs	1 (1–6)
Number of targeted sites	1 (1–5)
Radiofrequency time, s	790 (180–6150)
Procedure duration, min	180 (120–360)

Data are n (%), median (min-max) or mean ± SD.